Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mainz Biomed NV MYNZ

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.


NDAQ:MYNZ - Post by User

Post by pastafagolion Nov 23, 2024 10:59am
64 Views
Post# 36327377

Why stock is droppping

Why stock is dropppingThey withdrew their submission from FDA for breakthrough device designation after the FDA told them to expand trials for average risk particpants.  New data to be submitted in 2025.  Lots of new members pumping stock.  People bought in at 10-20 during IPOs so trying to pump stock.  Still coould be something great but extreme risk.  
<< Previous
Bullboard Posts
Next >>